Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice

Cancer Immunology, Immunotherapy

Volumn 64, Issue 10, 2015, Pages 1215-1227

  Stermann, Alexander ^a   Huebener, Nicole ^b   Seidel, Diana ^a   Fest, Stefan ^c   Eschenburg, Georg ^d   Stauder, Michael ^e   Schramm, Alexander ^e   Eggert, Angelika ^f   Lode, Holger N ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

DNA vaccination; Immunotherapy; MYCN; Neuroblastoma; Pediatric oncology

Indexed keywords

CD45 ANTIGEN; DNA VACCINE; MYCN ONCOGENE DNA VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; EPITOPE; LIVE VACCINE; MYCN PROTEIN, MOUSE; ONCOPROTEIN; PEPTIDE FRAGMENT; SALMONELLOSIS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BACTERIAL STRAIN; BACTERIUM CARRIER; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MAPPING; GENE TRANSFER; GENETIC TRANSCRIPTION; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PRIORITY JOURNAL; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; CYTOTOXICITY; EXPERIMENTAL MAMMARY NEOPLASM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; INBRED MOUSE STRAIN; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; TRANSGENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME; VACCINATION;

ADMINISTRATION, ORAL; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, B-LYMPHOCYTE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEUROBLASTOMA; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; TRANSGENES; TUMOR BURDEN; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA;

EID: 84940718466     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1733-1     Document Type: Article

References (47)

1. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202–2211
2. Yamada S (1990) Expression of c-myc and N-myc in mouse embryos during craniofacial development. Kokubyo Gakkai Zasshi 57:83–105
3. Zimmerman K, Alt FW (1990) Expression and function of myc family genes. Crit Rev Oncog 2:75–95
4. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L (2013) New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin Cancer Res 19:5814–5821
5. Sarkar AK, Nuchtern JG (2000) Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 60:1908–1913
6. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA (1997) DNA vaccines. Annu Rev Immunol 15:617–648
7. Matzinger P (2002) An innate sense of danger. Ann N Y Acad Sci 961:341–342
8. Krieg AM (2000) The role of CpG motifs in innate immunity. Curr Opin Immunol 12:35–43
9. Sizemore DR, Branstrom AA, Sadoff JC (1995) Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270:299–302
10. Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Forster-Wald E, Jensen-Jarolim E, Lode HN (2006) Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567–10575
11. Fest S, Huebener N, Bleeke M, Durmus T, Stermann A, Woehler A, Baykan B, Zenclussen AC, Michalsky E, Jaeger IS, Preissner R, Hohn O, Weixler S, Gaedicke G, Lode HN (2009) Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 125:104–114
12. Huebener N, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y, Gaedicke G, Lode HN (2008) A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 7:2241–2251
13. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219
14. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175
15. Whitton JL, Oldstone MB (1989) Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med 170:1033–1038
16. Whitton JL (1994) Induction of protective immunity using minigenes. Ann N Y Acad Sci 730:107–117
17. Huebener N, Lange B, Lemmel C, Rammensee HG, Strandsby A, Wenkel J, Jikai J, Zeng Y, Gaedicke G, Lode HN (2003) Vaccination with minigenes encoding for novel ‘self’ antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett 197:211–217
18. Lewen S, Zhou H, Hu H, Cheng T, Markowitz D, Reisfeld R, Xiang R, Luo Y (2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 57:507–515
19. Lode HN, Huebener N, Zeng Y, Fest S, Weixler S, Gaedicke G (2004) DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann N Y Acad Sci 1028:113–121
20. Berger E, Soldati R, Huebener N, Hohn O, Stermann A, Durmus T, Lobitz S, Zenclussen AC, Christiansen H, Lode HN, Fest S (2013) Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. Cancer Lett 331(2):167–173
21. Levine MM, Galen J, Barry E, Noriega F, Chatfield S, Sztein M, Dougan G, Tacket C (1996) Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol 44:193–196
22. Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Koster J, Vandesompele J, Vermeulen J, De Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH (2012) Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. Br J Cancer 107:1409–1417
23. Pajtler KW, Rebmann V, Lindemann M, Schulte JH, Schulte S, Stauder M, Leuschner I, Schmid KW, Kohl U, Schramm A, Eggert A (2013) Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. Int J Cancer 133:908–919
24. Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, Eggert A, Reisfeld RA, Lode HN (2007) Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 67:2331–2338
25. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166:5366–5373
26. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL (1993) A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 363:552–554
27. Sijts A, Zaiss D, Kloetzel PM (2001) The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol Med 1:665–676
28. Lode HN, Reisfeld RA (2000) Targeted cytokines for cancer immunotherapy. Immunol Res 21:279–288
29. Huebener N, Fest S, Hilt K, Schramm A, Eggert A, Durmus T, Woehler A, Stermann A, Bleeke M, Baykan B, Weixler S, Gaedicke G, Lode HN (2009) Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Mol Cancer Ther 8:2392–2401
30. Rennel E, Gerwins P (2002) How to make tetracycline-regulated transgene expression go on and off. Anal Biochem 309:79–84
31. Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D (2010) NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells. Cancer Res 70:916–924
32. Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A, Pistoia V (1996) Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma. Cancer Immunol Immunother 42:170–178
33. Martin RF, Beckwith JB (1968) Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 3:161–164
34. Pellat-Deceunynck C, Bataille R (2004) Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 32:293–301
35. Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, Widera G, Fuller JT, Kincaid C, Campbell IL, Whitton JL (1998) DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 72:5174–5181
36. Gerloni M, Zanetti M (2005) CD4 T cells in tumor immunity. Springer Semin Immunopathol 27:37–48
37. Groux H (2003) Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 75:8S–12S
38. Tudor D, Dubuquoy C, Gaboriau V, Lefevre F, Charley B, Riffault S (2005) TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23:1258–1264
39. Fruci D, Niedermann G, Butler RH, van Endert PM (2001) Efficient MHC class I-independent amino-terminal trimming of epitope precursor peptides in the endoplasmic reticulum. Immunity 15:467–476
40. Xiang R, Luo Y, Niethammer AG, Reisfeld RA (2008) Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 222:117–128
41. Spierings DC, Agsteribbe E, Wilschut J, Huckriede A (2000) Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes. Br J Cancer 82:1474–1479
42. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide–MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4:565–571
43. Christinck ER, Luscher MA, Barber BH, Williams David B (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352:67–70
44. Strehl B, Seifert U, Kruger E, Heink S, Kuckelkorn U, Kloetzel PM (2005) Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 207:19–30
45. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, Hill CP (2000) Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408:115–120
46. Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18:2740–2753
47. Heczey A, Louis CU (2013) Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med 16:287–294